A Phase 2 interventional study of frexalimab and brivekimig in Focal Segmental Glomerulosclerosis and Glomerulonephritis Minimal Lesion, sponsored by Sanofi. Recruiting at 82 sites in 22 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 10th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2024, is one of 29 in phase 2, reaches primary completion later than 3 of the 20 other live ones, and was the 62nd registered.
106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.
Browse Glomerulosclerosis, Focal Segmental studies →18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 34 more countries
Ages 12+
Akebia Therapeutics · Sites in United States
Ages 18+
Meyer Children's Hospital IRCCS · Sites in United States, Germany, Italy and 2 more countries
Ages 0–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 31 · Phase 3 5 · Phase 4 4
First in 1996; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 30 across 73 interventional studies indexed under Glomerulosclerosis, Focal Segmental.
Median enrollment 30 across the 56 interventional studies, 252 across the 13 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 69 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Glomerulosclerosis, Focal Segmental — fewer than ten, so there is no comparison to draw.
10 of the studies in Glomerulosclerosis, Focal Segmental with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01094327University of MiamiProteinuria in Pre and Post Transplant | 2026-11-30 |
| NCT06500702SanofiA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | 2026-12-23 |
| NCT07219121Travere Therapeutics, Inc.Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis | 2027-03 |
| NCT05583942Northwell HealthA Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) | 2027-03-01 |
| NCT05588063Northwell HealthtaVNS for FRNS in Children | 2027-03-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig or rilzabrutinib compared with placebo in participants with primary FSGS or MCD aged 16 to 75 years.
Study details for each participant include:
The study duration will be up to 52 weeks. The treatment duration will be 24 weeks. There will be up to 16 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Frexalimab active dose
Drug: frexalimab
Brivekimig active dose
Drug: brivekimig
Rilzabrutinib active dose
Drug: rilzabrutinib
Matching placebo
Drug: placebo
frexalimab treatment
brivekimig treatment
rilzabrutinib treatment
placebo treatment
Percent reduction in urine protein to creatinine ratio (UPCR)
Time frame: From baseline to Week 12
Percentage of participants achieving FSGS partial remission endpoint
Defined as UPCR ≤1.5 g/g and \>40 % reduction of UPCR from baseline
Time frame: At Week 12
Percentage of participants achieving CR
Defined as UPCR ≤0.3 g/g
Time frame: At Week 12
Incidence of treatment-emergent adverse events, treatment-emergent serious adverse events (SAEs), treatment-emergent adverse events of special interest (AESIs) and IMP discontinuation due to TEAEs during the study
TEAEs, including clinically significant changes in vital signs, electrocardiogram \[ECG\], and laboratory evaluation
Time frame: Treatment emergent period, up to Week 48
Plasma concentrations of frexalimab and rilzabrutinib and serum concentrations of SAR442970
Time frame: Up to Week 48
Occurrence of anti-drug antibodies (ADAs) against frexalimab and SAR442970
Time frame: Up to Week 48
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Frexalimab · Brivekimig · Rilzabrutinib
Glomerulosclerosis, Focal Segmental →